Radionuclide News and Research

RSS

Study opens new possibilities of tailoring radiopharmaceutical treatment to neuroendocrine cancer patients

A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) is likely to be effective in a patient with neuroendocrine cancer.

7 Apr 2023

New strategies to beat rare tumors of the adrenal gland

Only one in 100,000 people suffer from a pheochromocytoma, a tumor of the adrenal gland. If the tumor has already metastasized, a radioactive compound can be used to detect malignant cells that have spread to other parts of the body, and to irradiate them from the inside.

9 Feb 2023

Imaging method yields highly accurate and precise values of radionuclide organ uptake

Patients with cancer that has spread to the bone are sometimes treated with alpha particle radiation therapy that is delivered into or very close to the tumor.

16 Dec 2022

Novel molecular imaging radiotracer can precisely diagnose multiple cancers

A new molecular imaging radiotracer can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies.

20 Nov 2022

Research reveals molecular pathways of aggressive cribriform prostate cancer

Cribriform prostate cancer is an aggressive subtype of the disease characterized by its histology, but little is known about its molecular pathways.

26 Oct 2022

Duke biomedical engineers develop a two-pronged approach to treating pancreatic cancer

Biomedical engineers at Duke University have demonstrated the most effective treatment for pancreatic cancer ever recorded in mouse models.

21 Oct 2022

PSI researchers optimize a method for tumor diagnosis using radionuclides

Researchers at the Paul Scherrer Institute PSI, in collaboration with ETH Zurich, have optimized a method for tumor diagnosis using radionuclides.

5 Oct 2022

uPAR may be a promising target for therapy in patients with neuroendocrine neoplasms

A novel PET radiotracer can accurately assess the presence of a biomarker that indicates the level of tumor aggressiveness in neuroendocrine neoplasms (NENs).

28 Sep 2022

Researchers develop new precision medicine technology for cancer immunotherapy

In recent years, great advances have been made in the development of new successful immunotherapies to treat cancer. CAR T-cell therapy and antibody treatments are two types of targeted immunotherapies that have revolutionized areas of cancer care.

28 Feb 2022

Combination treatment can effectively inhibit tumor growth

Researchers at the Paul Scherrer Institute PSI have tested various methods to check how effective they are in combatting certain types of cancer.

15 Dec 2021

$Phase I trial evaluates safety, efficacy of astatine for use in alpha therapy for refractory thyroid cancer patients$

Phase I trial evaluates safety, efficacy of astatine for use in alpha therapy for refractory thyroid cancer patients

A research team from the Graduate School of Medicine at Osaka University has started an investigator-initiated clinical trial of sodium astatine ([211At]NaAt) injection for refractory differentiated thyroid cancer patients.

29 Nov 2021

Study proves safety and effectiveness of novel radionuclide therapy for neuroendocrine neoplasms

A new type of peptide receptor radionuclide therapy (PRRT) has been shown to control disease in 85 percent of patients with metastatic neuroendocrine neoplasms, achieving complete remission in some patients.

23 Nov 2021

New program sets out to change the European landscape for emerging medical radionuclides

The European medical radionuclides programme sets out to substantially change the European landscape for novel and emerging medical radionuclides.

23 Sep 2021

NFCR announces winners of 2021 Salisbury Award Competition

The National Foundation for Cancer Research (NFCR) announced winners of the 2021 Salisbury Award Competition for Entrepreneurial Translational Research, selected from among eight semi-finalists after pitch presentations in front of a judging committee consisting of prominent cancer research scientists, clinicians, early-stage investors and business leaders.

26 May 2021

New treatment for late-stage neuroendocrine tumors found to be more effective and less toxic

A new treatment for late-stage neuroendocrine tumors (NETs) has been found to be more effective and have fewer side effects than the current standard of care, according to research published in the March issue of The Journal of Nuclear Medicine.

22 Mar 2021

New system may offer improved options for cancer treatment

Improved options for cancer treatment are on the way, thanks to a new system developed at Los Alamos National Laboratory for producing alpha-emitting medical radioisotopes intended to target and overpower diseased tissue while sparing the healthy tissue around it.

11 Mar 2021

PRRT technology may offer new treatment approaches for neuroendocrine tumors

Neuroendocrine tumors are cancers that begin in specialized cells called neuroendocrine cells. These cells have traits similar to those of nerve cells and hormone-producing cells.

9 Mar 2021

Metal-containing radiopharmaceuticals could improve access to diagnostic imaging of AD

A team of researchers from the Laboratory of Biophysics at NUST MISIS, Lomonosov Moscow State University and D. Mendeleev University of Chemical Technology of Russia has summarized metal-containing diagnostic agents for positron emission tomography (PET), magnetic resonance imaging (MRI), and single-photon emission computed tomography (SPECT) imaging of Alzheimer's disease (AD).

9 Feb 2021

Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model

A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The Journal of Nuclear Medicine.

8 Feb 2021

Study investigates effect of anti-CD45 RIT lymphodepletion on immune cell types

Oncotarget recently published "Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy" which reported that Chimeric antigen receptor T cell therapies, and adoptive cell therapy in general, represent one of the most promising anti-cancer strategies.

12 Jan 2021